Frazier Life Sciences Management »

Rapt Therapeutics shares owned by Frazier Life Sciences Management

Quarter-by-quarter ownership of Rapt Therapeutics (RAPT) shares owned by Frazier Life Sciences Management from 13F filings

Historical chart of Frazier Life Sciences Management investment in Rapt Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapt Therapeutics held by Frazier Life Sciences Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapt Therapeutics by Frazier Life Sciences Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $33M 983k 33.87

More positions owned by Frazier Life Sciences Management

Newamsterdam Pharma Company Ordinary Shares (NAMS)
Mirum Pharmaceuticals (MIRM)
Arcutis Biotherapeutics (ARQT)
Bridgebio Pharma (BBIO)
Mbx Biosciences (MBX)
Phathom Pharmaceuticals (PHAT)
Maze Therapeatics (MAZE)
Trevi Therapeutics (TRVI)
Krystal Biotech (KRYS)
Disc Medicine (IRON)
Erasca (ERAS)
Kalvista Pharmaceuticals (KALV)
Palvella Therapeutics Inc Ne (PVLA)
Avidity Biosciences Ord (RNA)
Revolution Medicines (RVMD)

View all positions for Frazier Life Sciences Management

Top funds holding Rapt Therapeutics

TCG Crossover Management
Fcpm Iii Services B.v.
Rtw Investments
Foresite Capital Management VI
Siren
Vanguard Group
OrbiMed Advisors
Frazier Life Sciences Management
Ikarian Capital
Braidwell
Soleus Capital Management
Nantahala Capital Management
Caligan Partners
State Street Corporation
Dr. Jeffrey R. Jay, M.D.

View all funds holding Rapt Therapeutics